On April 13, 2026 ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin Vascular Targeted Photodynamic therapy (VTP) to treat a range of solid tumors, reported positive preliminary results from the Company’s ongoing Phase 1 study of Padeliporfin VTP treatment in patients with unresectable locally advanced pancreatic ductal adenocarcinoma (LA-PDAC). These data will be shared in a late-breaking podium presentation at the Society of Interventional Radiology (SIR) 2026 Annual Meeting taking place April 11-15, 2026 in Toronto, Canada. Early clinical observations of Padeliporfin in LA-PDAC support advancement of the program, while the Company is pursuing strategic partnering opportunities to support the commercialization of its low-grade upper tract urothelial carcinoma (UTUC) program.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These initial results from our ongoing trial in LA-PDAC spotlight the emerging clinical profile behind our strategic advancement of this program. At the lowest dose, Padeliporfin VTP has so far not only demonstrated a well-tolerated profile – consistent with the robust body of data generated across indications – but, importantly, also shown promising signs of clinical efficacy highlighting its potential to convert patients with unresectable tumors to become eligible for surgery," said Eyal Morag, M.D., Chief Medical Officer of ImPact Biotech. "For such a large, high-need set of patients with limited treatment options aside from surgery, Padeliporfin VTP has the potential to expand the treatable population by selectively ablating the tumor near major arteries to safely allow for resection of the residual tumor tissue. We are strongly encouraged by the initial responses from the first cohort and look forward to providing additional updates on the program this year."

The Phase 1 LA-PDAC trial is a two-part dose-escalation and expansion study evaluating Padeliporfin VTP in patients with vascular encasement deeming them ineligible for surgical resection. The primary objective in Part A of this trial is to assess safety and determine the optimal light dose to progress into Part B for further evaluation. Secondary objectives are to assess preliminary efficacy, as patients are evaluated following treatment to determine eligibility for pancreaticoduodenectomy (Whipple procedure).

As of December 4, 2025, the data cut-off for the podium presentation at SIR, three patients had completed follow-up from initial treatment in the lowest dose cohort (200 mW/cm) and were evaluable for potential surgery.

Key preliminary results from the Phase 1 study of Padeliporfin VTP in LA-PDAC:

Clinical Profile:

2 of the 3 (66%) patients successfully underwent surgery following Padeliporfin VTP treatment with low light dose of 200 mW/cm, with the third patient remaining ineligible for surgery due to a mesenteric tumor spread unrelated to the VTP procedure.

Safety and Tolerability Profile:

Padeliporfin VTP was well-tolerated with no complications observed related to arterial injury, thrombosis, ischemia, or other VTP-related morbidity, consistent with previous data obtained from prior clinical studies.
No select treatment-related adverse effects (sTRAE) or dose-limiting toxicities (DLT) were observed in any patients.

ImPact has completed patient enrollment in the second cohort of the Phase 1 dose-escalation study and expects to report additional data throughout 2026. Subject to future discussions with the U.S. Food and Drug Administration (FDA), the Company believes the program may have potential to move directly into a registrational study.

"Given PDAC’s large addressable market and potential for an efficient development path forward, this program represents a compelling near-term opportunity for ImPact," said Barak Palatchi, Chief Executive Officer of ImPact Biotech. "The significant platform potential demonstrated by Padeliporfin VTP across several indications has enabled us to strategically pursue opportunities with the greatest potential for patient impact and long-term value. While we continue to generate promising and validating results with our late-stage UTUC program, we believe that advancing this program with the right strategic partner, supported by a commercial infrastructure and resources to accelerate launch, will maximize its impact for patients and allow our team and resources to focus on what we do best."

Topline data from the Phase 3 ENLIGHTED trial in low-grade upper tract urothelial carcinoma (UTUC) and submission of a new drug application (NDA) for Padeliporfin VTP to the FDA are anticipated in 2026.

Presentation Details:

Title: Intra-Arterial (IA) Padeliporfin Vascular-Targeted Photodynamic Therapy (VTP): Ongoing Multicenter, Phase I Light Dose Escalation Study in Unresectable Locally Advanced Pancreatic Ductal Adenocarcinoma (LA-PDAC)

Presenter: Nadine Abi-Jaoudeh, M.D., Professor of Radiology, University of California, Irvine
Session Title: Late-breaking Abstracts 2
Session Date & Time: Monday, April 13, 2026, 4:21 PM ET

About PDAC
Pancreatic ductal adenocarcinoma (PDAC) is the third-leading cause of cancer deaths, with a five-year survival rate of approximately 10% – the lowest among all solid tumors. At diagnosis, only about 20% of patients have resectable or borderline resectable disease, while the remaining 80% present with unresectable tumors that are either locally advanced or have distant metastases. Patients with unresectable tumors have limited therapeutic options and while prognoses have improved significantly in the last decade, only about 5% of patients will survive for 10 years or more following diagnosis. Therapeutic options for treatable patients remain limited and underscore significant unmet need for innovative treatments that can improve survival and quality of life.

(Press release, ImPact Biotech, APR 13, 2026, View Source [SID1234664342])

On April 13, 2026 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, reported the completion of patient randomization in the Phase 2 part of the Phase 1/2 clinical trial evaluating TG4050, an individualized neoantigen therapeutic vaccine (INTV) developed from Transgene’s myvac platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

38 patients have been randomized in the Phase 2 part of the Phase 1/2 trial for adjuvant treatment of head and neck cancer (HNSCC1). With the primary endpoint of the trial being 2-year disease-free survival (DFS), Transgene is advancing the study and expects to communicate top line results by the end of Q1 2028.

TG4050 is designed to stimulate a strong and individualized immune response aimed at preventing relapse in patients following surgery and adjuvant (chemo)radiotherapy.

Dr. Alessandro Riva, MD, Chairman and CEO of Transgene, commented: "Completing randomization in the Phase 2 part of the study is an important milestone for TG4050 and for our myvac platform and confirms the expected readout timing of the primary endpoint of the Phase 1/2 trial by the end of Q1 2028, while we plan to release first immunological data in H2 2026. We are grateful to the patients, investigators and site personnel who contribute to advancing this promising, individualized immunotherapy. We look forward to the upcoming analyses as we continue our efforts to provide an innovative individualized treatment option for patients diagnosed with operable squamous head and neck cancer."

The primary objective of the randomized multicenter Phase 1/2 trial (NCT04183166) is to compare the efficacy of TG4050 as a single agent versus watchful waiting in the adjuvant treatment of locoregionally advanced HPV-negative head and neck cancer (HNSCC).

The primary endpoint of the trial is 2-year disease-free survival (DFS) and is expected to read out as soon as all patients from the Phase 2 part achieve 2-year follow-up from randomization unless an event (relapse, death) occurs earlier, with results anticipated by the end of Q1 2028.

Data from patients in the Phase 1 part of the trial have already shown that multiple subcutaneous injections of TG4050 were well-tolerated with no unexpected safety signals.
3-year DFS follow-up of Phase 1 patients is expected in Q2/Q3 2026.

TG4050, as a monotherapy, met all trial endpoints in the Phase 1 part of the trial and induced long-lasting immune responses to vaccine neoantigens that were sustained for up to two years after treatment initiation. All patients treated with TG4050 were disease-free at 2-years (median follow-up: 30 months), confirming robust clinical proof of principle.

The positive clinical and translational data2 suggest that individualized treatment with TG4050 has the potential to prevent cancer relapses when administered as monotherapy in an adjuvant treatment regimen in patients with high risk, resected, locally advanced HPV-negative HNSCC.

(Press release, Transgene, APR 13, 2026, View Source [SID1234664310])

On April 13, 2026 Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), reported follow-up histology tissue analysis data from its first-in-human early feasibility study of its Targeted Hyperthermia Therapy (‘THT’) in late stage melanoma patients who had failed on standard immunotherapy protocols (the "Study"). An extensive multiplex histological tissue analysis conducted at Dalhousie University of representative tissues from Study patients showed extensive natural killer cell infiltration in tumor tissues biopsied after treatment with THT indicative of innate immune activation. Also, analysis of samples from Study patients who only partially responded to the THT treatment showed a significant increase in T-regulatory cells and strong PD-L1 expression suggesting that these tumors may benefit from adding PD-1 immunotherapy in combination with Sona’s THT treatment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Carman Giacomantonio, Sona’s CMO, commented, "We are very proud and excited to report that the detailed histological tissue analysis from representative patient samples validates our pre-clinical findings. Our analysis confirms that patients responding to Sona’s THT treatment experienced a strong immunogenic response characterized by extensive innate immune activation with abundant macrophage infiltration and a robust natural killer cell infiltration. Notably, in partially responding patients, we observed a significant increase in T-regulatory cells and strong expression of PD-L1. The significance of this in response is these patients would be predicted to respond to PD-1 and CTLA-4 immunotherapy, particularly if administered in timely combination with our THT."

These results, together with our pre-clinical modelling studies, give us great confidence that immunotherapy response rates, which are typically below 20% for colorectal cancer, can be increased by first priming tumors with Sona’s THT therapy before administering immunotherapy, giving hope to the four out of five colorectal cancer sufferers for whom no treatment tends to work."

This histology tissue analysis, together with the Study’s protocol and other findings are now being prepared for submission to a scientific journal for peer review and publication.

In the Study, ten advanced-stage melanoma patients, all of whom were failing to respond to standard immunotherapy treatment, were recruited into this early feasibility study. Under the study protocol, patients had up to four tumors treated with Sona’s THT on days one and eight of the Study. By day 15, 8/10 patients experienced a clinical response to the THT treatment with a majority (6/8) showing no detectable residual melanoma in representative, biopsied tumors, with two patients showing no response.

(Press release, Sona Nanotech, APR 13, 2026, View Source [SID1234664327])

On April 13, 2026 LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, reported the presentation of preliminary results for a clinical trial testing the combination of Lixte’s proprietary compound LB100 in combination with Dostarlimab at the 2026 Conference of the Society of Gynecological Cancer, April 10-13, in San Juan, Puerto Rico.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The annual conference brings together a diverse group of specialists, including gynecologic oncologists, radiation oncologists, nurses, researchers and others to share the latest scientific advancements. It features exhibitors from various medical device and pharmaceutical companies, showcasing cutting-edge products and services tailored for the gynecologic cancer care team.

"The findings being presented provide new hope for patients with ovarian cancer, a disease that thus far has limited therapeutic options," said Bas van der Baan, LIXTE’s Chief Scientific Officer. "LIXTE’s proprietary compound, LB-100, combined with GSK’s anti PD1 drug Dostarlimab, has shown an acceptable safety profile. All 21 planned participants in the trial have been enrolled, and 20 were evaluated for efficacy in this interim analysis. Based on those favorable results, an additional cohort of 21 patients with a higher exposure to LB-100 is in the process of enrolling."

Trial Results

At a median follow-up length of 12 months (range 1.4-22), median OS has not been reached. However, OS probability was 0.84 (95%CI 0.64-0.94) at 6 months and 0.69 (95% CI 0.44-0.84) at 12 months. The Disease Control Rate was 40% (8/20, 95% CI 19.1-63.9%).

The trial is based on the observation by the lead clinical investigator Amir Jazaeri MD, Professor of Gynecologic Oncology at The University of Texas MD Anderson Cancer Center, that a genetically acquired reduction in PP2A activity may increase responsiveness to immune checkpoint blockade (ICB) in Ovarian Clear Cell Carcinoma (OCCC), particularly in tumors harboring somatic PPP2R1A mutations resulting in loss of protein phosphatase 2A (PP2A) function.

"We are learning more about the molecular features of ovarian clear-cell carcinomas that correlate with benefit from immune checkpoint inhibitors," said Dr. Jazaeri. "This study investigates how to use immunotherapy combinations such as Dostarlimab and LB-100 to expand the benefit for patients whose tumors do not carry these features."

Specifically, prior investigation reported markedly prolonged overall survival (OS) with ICB in patients with PPP2R1A-mutant OCCC (66.9 months versus 9.2 months for patients with wild-type tumors). This suggested that reducing PP2A pharmacologically with LB-100 may enhance the anti-tumor effect of the PD-1 blocking monoclonal antibody, dostarlimab-gxly, in patients with Ovarian Clear Cell Carcinoma lacking the genetic reduction in PP2A.

(Press release, Lixte Biotechnology, APR 13, 2026, View Source [SID1234664343])

On April 13, 2026 Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Children’s Hospital of Philadelphia (CHOP), the nation’s first pediatric hospital, reported a strategic collaboration to accelerate the discovery, development and nationwide availability of specialized pediatric diagnostics. By combining CHOP’s pediatric research and clinical expertise with Labcorp’s national diagnostic infrastructure, scientific capabilities and commercialization expertise, the collaboration aims to expand access to advanced diagnostic testing for children and families across the country.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our shared aim to improve children’s health makes this collaboration so powerful," said Stephen R. Master, M.D., Ph.D., division chief and director of metabolic and advanced diagnostics at Children’s Hospital of Philadelphia. "By pairing CHOP’s pediatric leadership with Labcorp’s nationwide reach, we seek to deliver important new and specialized tests to children and their families more efficiently and at greater scale."

Innovation Pipeline to Advance Pediatric Diagnostic Development
At the core of the collaboration is the creation of a joint pediatric diagnostics innovation pipeline where CHOP and Labcorp will team up to identify, develop and expand new tests and technologies with a goal of streamlining the path from discovery to national availability. Pediatric-specific diagnostics deliver more accurate, age-appropriate insights for children by accounting for their unique biology, developmental stages and physiological ranges—factors that traditional adult-oriented tests often overlook. The collaboration will make novel diagnostics available nationwide across key clinical areas, such as oncology, metabolic disease and autoimmune conditions.

Expanding Nationwide Access to Advanced Pediatric Testing
Together, the organizations will provide clinicians and health systems with cutting-edge pediatric testing—bringing breakthrough diagnostics in cancer, genetics, immune disorders and rare diseases to patients sooner and enabling earlier, more precise diagnoses.

"Labcorp and CHOP share a commitment to advancing pediatric care. By combining CHOP’s deep pediatric expertise with Labcorp’s scientific capabilities and national reach, we can bring pediatric diagnostic innovations to patients faster and make advanced testing accessible to many more families," said Bryan Vaughn, executive vice president, Diagnostics at Labcorp.

"Today’s announcement marks an important milestone at the intersection of scientific research and collaboration," said Joseph Mitchell, M.D., president at Children’s Hospital of Philadelphia. "Our commitment to innovation has always been driven by one goal: improving the lives of children. By working closely with Labcorp, we can create the breakthroughs that children and families need – today and in the years to come."

(Press release, LabCorp, APR 13, 2026, View Source [SID1234664311])